Last Updated: September 24, 2026

Details for New Drug Application (NDA): 017407

✉ Email this page to a colleague

NDA 017407 describes CATAPRES, which is a drug marketed by Boehringer Ingelheim and Lavipharm and is included in two NDAs. Additional details are available on the CATAPRES profile page.

The generic ingredient in CATAPRES is clonidine. There are two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clonidine profile page.

Summary for 017407

Tradename:	CATAPRES
Applicant:	Boehringer Ingelheim
Ingredient:	clonidine hydrochloride
Patents:	0

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	0.1MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	Approved Prior to Jan 1, 1982	TE:		RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	0.2MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	Approved Prior to Jan 1, 1982	TE:		RLD:	Yes

Profile for product number 003

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	0.3MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	Approved Prior to Jan 1, 1982	TE:		RLD:	Yes

Expired US Patents for NDA 017407

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-001	Approved Prior to Jan 1, 1982	⤷ Start Trial	⤷ Start Trial
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-003	Approved Prior to Jan 1, 1982	⤷ Start Trial	⤷ Start Trial
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-002	Approved Prior to Jan 1, 1982	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.